AOD-9604 vs Semaglutide: Research Peptide vs FDA-Approved
Here is how these two compounds compare — based on published research, not marketing claims.
AOD-9604
20
Indexed Studies
Animal Studies
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
Semaglutide
4520
Indexed Studies
FDA Approved
Evidence Level
Yes
Human Trials
FDA-Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
This comparison is not between equals. Semaglutide is an FDA-approved medication with thousands of published studies and multiple completed Phase III programs. AOD-9604 is a research peptide whose clinical development for obesity was discontinued. Understanding why both appear in the same conversations — and why the evidence gap matters — is the point of this comparison.
Key Differences
| Attribute | AOD-9604 | Semaglutide |
|---|---|---|
| Evidence Level | Animal Studies | FDA Approved |
| Category | HGH Fragment | GLP-1 Receptor Agonist |
| Human Data | One Phase IIb trial that did not meet its primary endpoint for weight loss. A few smaller studies. Clinical development for obesity was discontinued. | Extensive. STEP trials demonstrated 15-17% mean weight loss. SELECT trial demonstrated cardiovascular benefit. Multiple global Phase III programs completed. |
| Safety Profile | Limited human safety data. Phase IIb trial showed no serious safety concerns but also failed to demonstrate statistically significant weight loss. Generally considered well-tolerated. | Extensively characterized. GI side effects (nausea, vomiting) are common but typically transient. Rare risks include pancreatitis. Thousands of patient-years of safety data. |
| Key Limitations | Failed to demonstrate efficacy in its pivotal trial. Very limited human evidence. Clinical program was not continued. | GI side effects limit tolerability for some patients. Cost and access are barriers. Weight regain after discontinuation is documented. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
AOD-9604
A fragment of human growth hormone (amino acids 176-191) that retains fat-metabolizing activity without the growth-promoting effects of full HGH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood sugar or growth.
Semaglutide
Activates GLP-1 receptors throughout the body — in the brain (reducing appetite), gut (slowing emptying), and pancreas (regulating insulin). The result is a coordinated reduction in food intake and metabolic improvement.
Completely different approaches. AOD-9604 targets fat cells directly — telling them to break down stored fat. Semaglutide targets appetite and metabolism systemically — reducing how much you eat and improving how your body processes energy. Semaglutide addresses the behavioral and hormonal drivers of obesity. AOD-9604 attempts to address fat storage at the cellular level.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 4,540 indexed studies. Here are the key findings.
This is the largest evidence gap in any comparison on PSI. Semaglutide is L4 with thousands of studies, multiple FDA approvals, and completed cardiovascular outcome data. AOD-9604 is L2 with a discontinued clinical program and a pivotal trial that failed to show efficacy. These are not in the same category of evidence.
For evidence-based weight management, semaglutide has an incomparably stronger research foundation.
For understanding fat metabolism mechanisms, AOD-9604 provides interesting preclinical data about HGH fragment activity.
For clinical decision-making, semaglutide is the only compound here with proven efficacy in controlled trials.
AOD-9604's newer osteoarthritis research direction may prove more promising than its original obesity indication.
Key Limitations
- •This comparison is inherently lopsided — one compound has L4 evidence, the other has L2.
- •AOD-9604's clinical program for obesity was discontinued after failing its efficacy endpoint.
- •Comparing an FDA-approved medication to a discontinued research compound has limited clinical utility.
- •Cost, access, and prescription requirements differ fundamentally between these options.
PSI Verdict
SUPPORTED BY EVIDENCE
Semaglutide produces clinically meaningful weight loss (15-17% mean) in large randomized controlled trials and reduces cardiovascular risk. AOD-9604 stimulates lipolysis in preclinical models. These are not comparable levels of evidence.
NOT YET ESTABLISHED
AOD-9604 has not demonstrated statistically significant weight loss in humans. Whether its mechanism of action can produce clinically meaningful results at achievable doses is unproven.
CONFIDENCE LEVEL
Very high for semaglutide — this is one of the best-studied compounds in medicine. Very low for AOD-9604 for weight management — its own clinical trial did not support efficacy. If you are comparing these for a weight management decision, the data overwhelmingly supports semaglutide.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
AOD-9604
"AOD-9604 burns fat without affecting muscle"Plausible but modest effect
"AOD-9604 helps with joint pain too"Insufficient evidence
Semaglutide
"I lost 30+ pounds on Ozempic without changing anything else"Supported by evidence
"Ozempic face is a real thing — I look ten years older"Supported by evidence
"The nausea goes away after a few weeks"Supported by evidence
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
AOD-9604
Limited human safety data. Phase IIb trial showed no serious safety concerns but also failed to demonstrate statistically significant weight loss. Generally considered well-tolerated.
Semaglutide
Extensively characterized. GI side effects (nausea, vomiting) are common but typically transient. Rare risks include pancreatitis. Thousands of patient-years of safety data.
Semaglutide has extensive safety data from thousands of patients across multiple years. AOD-9604 showed no serious safety concerns in limited trials, but the dataset is too small for meaningful safety characterization. Semaglutide's risks are well-quantified. AOD-9604's are largely unknown.
WHAT THE RESEARCH SUGGESTS
There is no evidence-based case for choosing AOD-9604 over semaglutide for weight management. Semaglutide has proven efficacy, FDA approval, and cardiovascular outcome data. AOD-9604 failed its pivotal trial. This comparison exists because both appear in peptide therapy discussions, not because they are equivalent options.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.